Background macular Shape Background macular Shape Background macular Shape
News > Article
Macular Degeneration Research

Discovering Inflammatory Triggers in AMD

Sarah Doyle, PhD
Sarah Doyle, PhD

What: Toll-like receptor 2 (TLR2) is revealed to be a bridge between oxidative damage and inflammation in AMD.

Where: Toll-like Receptor 2 Facilitates Oxidative Damage-Induced Retinal Degeneration,” Cell Reports, 2020 (cover story)

BrightFocus ConnectionMacular Degeneration Research (MDR) Grantee Sarah Doyle, PhD of Trinity College Dublin, is a senior author of a report resulting from her BrightFocus-funded project.

Why It Is Important: The retina and surrounding retinal pigmented epithelial (RPE) cells are exposed to oxidative stress from things like smoking, poor diet, alcohol use, and aging, as well as from external threats such as second-hand smoke and other pollution, and radiation. Gradually these exposures contribute to the rise of reactive oxygen species (ROS, also known as “free radicals”) that damage cells. Numerous studies report a link between oxidative stress and age-related macular degeneration (AMD).

The February 18 issue of Cell Reports featured the BrightFocus-funded work of Sarah Doyle and colleagues on its cover.
The February 18 issue of Cell Reports featured the BrightFocus-funded work of Sarah Doyle and colleagues on its cover. Their image shows the honeycomb structure of retinal pigment epithelial cells, which are damaged in AMD. | Copyright Elsevier

In this study, the authors investigated an underlying mechanism by studying the contribution of toll-like receptors (TLRs) in the pathogenesis of AMD. TLRs are key sensors of damage that are used by our immune system. Activation of TLRs in turn triggers a multitude of signaling pathways that influence the type and duration of inflammatory response.

This study describes TLR2 as a possible link between oxidative damage and excessive inflammation seen in AMD and other types of retinal degeneration. Under conditions of oxidative stress, even in the absence of active infection, TLR2 activates components of the immune system that defend against infections, resulting in so-called “sterile” inflammation” that has been linked with AMD. A deficiency or blockade of TLR2 signaling protected RPE cells against oxidative damage, suggesting a possible new treatment approach.

About BrightFocus Foundation

BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. Through its flagship research programs — Alzheimer’s Disease Research, Macular Degeneration Research, and National Glaucoma Research— the Foundation has awarded nearly $300 million in groundbreaking research funding over the past 51 years and shares the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at brightfocus.org.

Disclaimer: The information provided here is a public service of BrightFocus Foundation and is not intended to constitute medical advice. Please consult your physician for personalized medical, dietary, and/or exercise advice. Any medications or supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical products or therapies.

Share this post